PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPa axis in HPV negative head and neck squamous cell carcinoma

被引:93
|
作者
Yu, Guang-Tao [1 ,2 ]
Bu, Lin-Lin [1 ,2 ]
Huang, Cong-Fa [1 ,2 ]
Zhang, Wen-Feng [3 ]
Chen, Wan-Jun [4 ]
Gutkind, J. Silvio [4 ]
Kulkarni, Ashok B. [5 ]
Sun, Zhi-Jun [1 ,2 ,3 ,5 ]
机构
[1] Wuhan Univ, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol, Wuhan 430072, Peoples R China
[2] Wuhan Univ, Minist Educ, Key Lab Oral Biomed, Wuhan 430072, Peoples R China
[3] Wuhan Univ, Sch & Hosp Stomatol, Depy Oral Maxillofacial Head Neck Oncol, Wuhan 430072, Peoples R China
[4] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, Lab Cell & Dev Biol, NIH, Bethesda, MD USA
[5] Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD USA
基金
中国国家自然科学基金;
关键词
HNSCC; myeloid-derived suppressor cell; tumor associated macrophagy; PD-1; T-CELL; HUMAN-PAPILLOMAVIRUS; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; PROGRAMMED DEATH-1; ADVANCED MELANOMA; CANCER; SURVIVAL; EXPRESSION;
D O I
10.18632/oncotarget.5955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) play key roles in the tumor immune suppressive network and tumor progression. However, precise roles of programmed death-1 (PD-1) in immunological functions of MDSCs and TAMs in head and neck squamous cell carcinoma (HNSCC) have not been clearly elucidated. In the present study, we show that PD-1 and PD-L1 levels were significantly higher in human HNSCC specimen than in normal oral mucosa. MDSCs and TAMs were characterized in mice and human HNSCC specimen, correlated well with PD-1 and PD-L1 expression. aPD-1 treatment was well tolerated and significantly reduced tumor growth in the HNSCC mouse model along with significant reduction in MDSCs and TAMs in immune organs and tumors. Molecular analysis suggests a reduction in the CD47/SIRPa pathway by PD-1 blockade, which regulates MDSCs, TAMs, dendritic cell as well as effector T cells. Hence, these data identify that PD-1/PD-L1 axis is significantly increased in human and mouse HNSCC. Adoptive aPD-1 immunotherapy may provide a novel therapeutic approach to modulate the micro-and macro-environment in HNSCC.
引用
收藏
页码:42067 / 42080
页数:14
相关论文
共 50 条
  • [41] Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
    Beck, Tim N.
    Kaczmar, John
    Handorf, Elizabeth
    Nikonova, Anna
    Dubyk, Cara
    Peri, Suraj
    Lango, Miriam
    Ridge, John A.
    Serebriiskii, Ilya G.
    Burtness, Barbara
    Golemis, Erica A.
    Mehra, Ranee
    ONCOTARGET, 2015, 6 (22) : 18863 - 18874
  • [42] Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells
    Anna R. Bopp
    Felipe F. Lamenza
    Puja Upadhaya
    Nathan M. Ryan
    Natalie Kazmierowicz
    Pete P. Jordanides
    Arham Siddiqui
    Sherefuddin H. Pracha
    Peyton Roth
    O. Hans Iwenofu
    Steve Oghumu
    Cancer Immunology, Immunotherapy, 74 (7)
  • [43] Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
    Solomon, Benjamin
    Young, Richard J.
    Bressel, Mathias
    Urban, Damien
    Hendry, Shona
    Thai, Alesha
    Angel, Christopher
    Haddad, Afaf
    Kowanetz, Marcin
    Fua, Tsien
    Corry, June
    Fox, Stephen
    Rischin, Danny
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (03) : 295 - 304
  • [44] Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
    Ma, Si-Rui
    Deng, Wei-Wei
    Liu, Jian-Feng
    Mao, Liang
    Yu, Guang-Tao
    Bu, Lin-Lin
    Kulkarni, Ashok B.
    Zhang, Wen-Feng
    Sun, Zhi-Jun
    MOLECULAR CANCER, 2017, 16
  • [45] CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits
    Oh, Se-Yeong
    Kang, Hyun Jung
    Kim, Young Sook
    Kim, Hyunggee
    Lim, Young Chang
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 272 - 280
  • [46] PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas
    Sanchez-Canteli, Mario
    Granda-Diaz, Rocio
    del Rio-Ibisate, Nagore
    Allonca, Eva
    Lopez-Alvarez, Fernando
    Agorreta, Jackeline
    Garmendia, Irati
    Montuenga, Luis M.
    Garcia-Pedrero, Juana M.
    Rodrigo, Juan P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (10) : 2089 - 2100
  • [47] CTLA-4 blockade induces tumor pyroptosis via CD8+T cells in head and neck squamous cell carcinoma
    Wang, Shuo
    Wu, Zhi-Zhong
    Zhu, Su-Wen
    Wan, Shu-Cheng
    Zhang, Meng-Jie
    Zhang, Bo-Xin
    Yang, Qi-Chao
    Xiao, Yao
    Li, Hao
    Mao, Liang
    Wang, Zhi-Yong
    Gutkind, J. Silvio
    Sun, Zhi-Jun
    MOLECULAR THERAPY, 2023, 31 (07) : 2154 - 2168
  • [48] Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival
    Gubanova, Evgenia
    Brown, Brandee
    Ivanov, Sergei V.
    Helleday, Thomas
    Mills, Gordon B.
    Yarbrough, Wendell G.
    Issaeva, Natalia
    CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1257 - 1267
  • [49] Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
    Abulizi, Adila
    Yan, Guangpeng
    Xu, Qian
    Muhetaer, Reyihanguli
    Wu, Shihan
    Abudukelimu, Kudelaiti
    Chen, Xi
    Liu, Chengjiang
    Li, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma
    Ihara, Fumie
    Sakurai, Daiju
    Horinaka, Atsushi
    Makita, Yuji
    Fujikawa, Akira
    Sakurai, Toshioki
    Yamasaki, Kazuki
    Kunii, Naoki
    Motohashi, Shinichiro
    Nakayama, Toshinori
    Okamoto, Yoshitaka
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (10) : 1275 - 1285